{"gene":"P2RY11","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":1999,"finding":"P2Y11 receptor is dually coupled to both phosphoinositide (PLC) and adenylyl cyclase (cAMP) pathways upon activation by ATP. The rank order of agonist potency was: ATPγS ≈ BzATP > dATP > ATP > ADPβS > 2MeSATP. Suramin acted as a competitive antagonist (Ki ~0.82 µM). AR-C67085 was identified as the most potent agonist.","method":"Stable recombinant expression in 1321N1 astrocytoma cells (IP3 assay) and CHO-K1 cells (cAMP assay); pharmacological characterization with agonists and antagonists","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro pharmacological reconstitution in two independent cell lines, replicated across multiple nucleotides and pathways","pmids":["10578132"],"is_preprint":false},{"year":2001,"finding":"P2Y11 receptor mediates ATP-induced maturation of human monocyte-derived dendritic cells through the P2Y11/cAMP/protein kinase A signaling pathway. The rank order of potency of ATP analogs matched the P2Y11 receptor profile, and the PKA inhibitor H89 blocked nucleotide-induced DC maturation (CD83 upregulation and IL-12 secretion).","method":"Pharmacological profiling with P2Y11-selective agonists/antagonists; PKA inhibitor (H89) functional assay; cAMP measurement in DCs","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological approaches in primary human cells, single lab, no siRNA/knockout confirmation","pmids":["11390464"],"is_preprint":false},{"year":2001,"finding":"The P2Y11 gene and the adjacent SSF1 gene are co-transcribed and undergo intergenic splicing, producing a chimeric P2Y11-SSF1 fusion transcript that is ubiquitously expressed in human tissues. The fusion protein retains P2Y11 receptor function (cAMP response to ATP) when stably expressed in CHO-K1 cells.","method":"cDNA library screening; RT-PCR; stable expression in CHO-K1 cells; cAMP assay; Western blotting","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct molecular cloning with functional validation, single lab","pmids":["11278528"],"is_preprint":false},{"year":2001,"finding":"Coupling of the human P2Y11 receptor to adenylyl cyclase is significantly weaker than coupling to phospholipase C (ATP is ~15-fold less potent for cAMP vs. IP accumulation). PKC activation and intracellular Ca2+ mobilization (downstream of PLC) potentiate P2Y11-mediated cAMP accumulation, indicating cross-talk between the two signaling arms.","method":"Stable expression in 1321N1 and CHO cells; IP/cAMP assays; PKC downregulation with phorbol ester; intracellular Ca2+ chelation with BAPTA","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal biochemical approaches in two independent cell lines, rigorous controls","pmids":["11156592"],"is_preprint":false},{"year":2001,"finding":"The canine P2Y11 receptor shows preferential activation by ADP nucleotides (opposite to the human P2Y11 which prefers ATP nucleotides). Mutational analysis revealed that Arg-265 at the juxtaposition of TM6 and the third extracellular loop in hP2Y11 is a key determinant of triphosphate selectivity; substituting it with glutamine (as found in cP2Y11) shifts selectivity toward diphosphates.","method":"Stable expression of human and canine P2Y11 in CHO-K1 and 1321N1 cells; IP/cAMP assays; Ca2+ mobilization; site-directed mutagenesis of Arg265","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — site-directed mutagenesis with functional readout in multiple cell lines, orthogonal assays","pmids":["11723245"],"is_preprint":false},{"year":2001,"finding":"P2Y11 receptor couples to Gs to directly activate adenylyl cyclase in canine MDCK-D1 cells, stimulating PI hydrolysis, Ca2+ mobilization, and cAMP accumulation. Microscopy and short-circuit current measurements demonstrated primarily basolateral targeting of P2Y11 receptors in polarized MDCK-D1 cell monolayers.","method":"Cloning and stable expression of cP2Y11-GFP; fluorescence microscopy; Ussing chamber electrophysiology; PKC inhibition; eicosanoid inhibition controls","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization with functional consequence (basolateral Isc response), single lab","pmids":["11408597"],"is_preprint":false},{"year":2002,"finding":"P2Y11 receptors in MDCK-D1 cells activate adenylyl cyclase via Gs, producing indo-resistant cAMP. ADP analogs (ADPβS, MT-ADP) activated adenylyl cyclase in MDCK membranes directly, and the response was synergistic with forskolin, confirming Gs-coupling. Overexpressed GFP-tagged P2Y11 receptors confirmed this pharmacological profile.","method":"Stable expression of GFP-tagged P2Y11 in MDCK-D1 cells; cAMP assays; adenylyl cyclase activity assay in membranes; antagonist pharmacology; indomethacin treatment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct adenylyl cyclase assay in membranes plus cell-based cAMP, single lab","pmids":["11788591"],"is_preprint":false},{"year":2003,"finding":"UTP activates a Ca2+ mobilizing response at P2Y11 receptors that is mechanistically distinct from the ATP-mediated response: UTP-induced Ca2+ is less dependent on extracellular Ca2+, is sensitive to pertussis toxin (unlike ATP), and is more easily desensitized. No P2Y2 or P2Y4 mRNA was detected in the expressing cells, confirming the response is P2Y11-mediated. This represents agonist-specific (biased) signaling at a single receptor.","method":"Stable expression in 1321N1 cells; intracellular Ca2+ measurements; RT-PCR for P2Y2/P2Y4; pertussis toxin pretreatment; 2-APB treatment; desensitization experiments","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal pharmacological/molecular methods, single lab","pmids":["12761346"],"is_preprint":false},{"year":2003,"finding":"P2Y11 receptor activation inhibits migration of monocyte-derived DCs (MoDCs) and CD1a+ dermal DCs in a dose-dependent manner. On maturation, MoDCs downregulated P2Y11 receptor expression and became less sensitive to ATP-mediated migration inhibition. Blood DC subtypes did not respond to P2Y11R agonists despite mRNA expression, indicating post-transcriptional regulation of functional receptor expression.","method":"P2Y receptor agonist/antagonist pharmacology; Ca2+ flux studies; migration assays; flow cytometry; RT-PCR","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple DC populations, pharmacological and receptor expression approaches, functional migration assay, single lab","pmids":["12649135"],"is_preprint":false},{"year":2006,"finding":"Extracellular β-NAD+ is an agonist of the P2Y11 receptor. In hP2Y11-transfected 1321N1 astrocytoma cells, but not untransfected cells, NAD+ promoted IP3, cAMP, and cADPR production and biphasic Ca2+ elevation. In human granulocytes, selective P2Y11 inhibition (NF157) and P2Y11 siRNA knockdown prevented NAD+-induced Ca2+ increase and chemotaxis.","method":"Stable transfection in 1321N1 cells; IP3/cAMP/cADPR measurements; Ca2+ imaging; siRNA knockdown; pharmacological inhibition with NF157 in primary granulocytes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in transfected cells plus siRNA in primary cells, multiple second messengers measured, replicated across cell types","pmids":["16926152"],"is_preprint":false},{"year":2007,"finding":"P2Y11 receptor mediates ATP-induced inhibition of neutrophil apoptosis via downstream activation of type I cAMP-dependent protein kinases (PKA). Brief (10 min) ATP exposure caused long-lasting apoptosis delay. The P2Y11 antagonist NF157 abrogated the anti-apoptotic effect; the mechanism was not mediated by adenosine (ATP breakdown product).","method":"Morphology, annexin V/To-Pro3 staining, mitochondrial membrane permeabilization assay; NF157 antagonism; PKA inhibition; receptor expression studies; cAMP measurements","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple apoptosis readouts and signaling inhibitors, single lab","pmids":["18056402"],"is_preprint":false},{"year":2007,"finding":"NAADP+ is an agonist of the human P2Y11 receptor. In hP2Y11-transfected 1321N1 cells (but not wild-type), extracellular NAADP+ triggered concentration-dependent biphasic Ca2+ elevation via IP3 (rapid phase) and cAMP/cADPR (sustained phase). In human granulocytes, NF157 confirmed endogenous P2Y11 mediated NAADP+-induced cell activation.","method":"Stable transfection in 1321N1 cells; IP3/cAMP/cADPR measurements; Ca2+ imaging; NF157 pharmacological inhibition in primary granulocytes","journal":"Cell calcium","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in transfected vs. wild-type cells, multiple second messengers, confirmed in primary cells","pmids":["17707504"],"is_preprint":false},{"year":2007,"finding":"Computational homology modeling combined with mutagenesis identified the ligand-binding site residues of P2Y11: Arg106, Glu186, Arg268, and Arg307 interact ionically with ATP phosphate moieties; Tyr261 acts as a molecular switch (Y261A mutant is inactive); Phe109 provides minor π-stacking with adenine; Ser206 H-bonds to γ-phosphate; Ala313 contributes to a hydrophobic pocket near C-2 of ATP. Gs coupling efficacy was more variable across mutants than Gq coupling.","method":"Homology modeling with bovine rhodopsin and hP2Y1-ATP templates; site-directed mutagenesis of Arg106, Glu186, Arg268, Arg307, Phe109, Tyr261, Ser206, Ala313, Met310; Ca2+ and cAMP functional assays","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple point mutations with functional readouts across two signaling pathways, rigorous structure-function analysis","pmids":["17338680"],"is_preprint":false},{"year":2008,"finding":"P2Y11 and P2Y1 receptors form hetero-oligomers when co-expressed. This association (detected by co-pulldown, immunoprecipitation, and FRET) promotes agonist-induced internalization of P2Y11, which by itself cannot undergo endocytosis. P2Y11 co-internalized with P2Y1 upon ATP or P2Y1-selective agonist (2-MeS-ADP) stimulation, and siRNA knockdown of endogenous P2Y1 in HEK293 cells reduced GFP-P2Y11 endocytosis. The hetero-oligomerization also altered ligand selectivity of P2Y11.","method":"Co-pulldown; immunoprecipitation; FRET; siRNA knockdown of P2Y1; Ca2+ imaging; stable co-expression in HEK293 and 1321N1 cells","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — three orthogonal methods (co-IP, pulldown, FRET) for complex detection, functional internalization confirmed by siRNA, single lab but multiple approaches","pmids":["17824841"],"is_preprint":false},{"year":2008,"finding":"Arg268 in TM6 is the principal determinant of P2Y11 receptor stereospecificity for Pα-substituted ATP derivatives. R268A and R268Q mutations abolished stereoselective recognition of ATP-α-S isomers. Glu186A mutation increased stereoselectivity. The double mutant R268Q/E186A showed additive decrease in potency but no additional stereoselectivity change.","method":"Site-directed mutagenesis; Ca2+ assay with purified diastereomers of ATP-α-S; molecular modeling","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous mutagenesis with purified stereoisomers, multiple mutants with systematic structure-activity analysis","pmids":["18820714"],"is_preprint":false},{"year":2009,"finding":"NF546 is the first selective non-nucleotide P2Y11 agonist, acting at the same binding site as ATPγS (as shown by competitive Schild analysis with antagonist NF340, pA2 = 8.02–8.04). NF546 stimulated IL-8 release from monocyte-derived dendritic cells, a P2Y11-mediated effect blocked by NF340.","method":"Schild analysis; Ca2+ and cAMP assays in transfected 1321N1 cells; molecular modeling; IL-8 ELISA in primary DCs; NF340 antagonism","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1 / Strong — competitive pharmacology (Schild analysis) plus functional assays in both recombinant and primary cells, rigorous binding-site characterization","pmids":["19815812"],"is_preprint":false},{"year":2010,"finding":"The disease-associated P2RY11 SNP (rs2305795) correlates with reduced P2Y11 expression in CD8+ T lymphocytes and NK cells, and reduced P2Y11-mediated resistance to ATP-induced cell death in these cells. This identifies P2Y11 as a regulator of immune-cell survival.","method":"Genome-wide association study with replication; eQTL analysis; flow cytometry for cell death in T and NK cells","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell death assay linked to expression levels, replicated across ethnic groups, but mechanism is expression-level rather than direct biochemical","pmids":["21170044"],"is_preprint":false},{"year":2010,"finding":"P2Y11 receptor activation by extracellular NAD+ (released via Connexin 43 hemichannels) mediates an autocrine cAMP/cADPR/Ca2+ signaling cascade in human mesenchymal stem cells, involving L-type Ca2+ channel opening. This signaling promoted MSC proliferation, migration, prostaglandin E2 release, cytokine release, and downregulation of T lymphocyte proliferation.","method":"Cx43 siRNA; NAD+ glycohydrolase treatment; P2Y11 siRNA; cAMP/cADPR/Ca2+ measurements; L-type channel pharmacology; functional assays (proliferation, migration)","journal":"Stem cells and development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown of P2Y11 and Cx43 with multiple functional readouts, single lab","pmids":["20964598"],"is_preprint":false},{"year":2010,"finding":"P2Y11 receptor activation on NK cells mediates ATP-induced inhibition of CX3CL1-directed NK cell chemotaxis and cytotoxicity against endothelial cells. This inhibitory effect correlated with increased intracellular cAMP. Pharmacological inhibition of P2Y11R (or apyrase addition) removed the protective effect on endothelial cells from NK-mediated killing.","method":"Pharmacological inhibition of P2Y11R; cAMP measurement; chemotaxis assay; NK cell cytotoxicity assay against HUVECs and coronary artery ECs","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in primary cells with pharmacological tools, single lab","pmids":["20668227"],"is_preprint":false},{"year":2013,"finding":"ATP release via vesicular exocytosis (VNUT/SLC17A9-dependent) followed by autocrine P2Y11 receptor activation is a major pathway for LPS-induced macrophage activation and cytokine release. Knockdown of SLC17A9, NF157 (P2Y11 antagonist), or P2Y11 siRNA knockdown suppressed M1 polarization and IL-6 production in THP-1 cells. In vivo, NF157 suppressed LPS-induced proinflammatory cytokines and macrophage M1 polarization.","method":"siRNA knockdown of SLC17A9 and P2Y11; ATP release measurement; pharmacological inhibition with NF157; in vivo LPS mouse model","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA knockdown of both upstream transporter and receptor with multiple functional readouts, validated in vivo, multiple orthogonal approaches","pmids":["23577075"],"is_preprint":false},{"year":2013,"finding":"P2Y11 receptor mediates IFN-γ-induced IL-6 production in human keratinocytes (HaCaT cells) via an autocrine ATP loop. IFN-γ stimulated ATP release; NF157 (P2Y11 antagonist), apyrase, suramin, and P2Y11 knockdown all suppressed IL-6 production. A soluble adenylate cyclase inhibitor (KH7) also blocked the effect, implicating cAMP signaling.","method":"P2Y11 siRNA knockdown; pharmacological inhibitors (NF157, suramin, apyrase, KH7); IL-6 ELISA; ATP release measurement","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA plus multiple pharmacological approaches, single lab","pmids":["23461851"],"is_preprint":false},{"year":2014,"finding":"The Ala-87-Thr (A87T) polymorphism of P2Y11 impairs signaling (reduced Ca2+ response to BzATP, reduced cAMP) and completely abolishes agonist-induced receptor internalization in HEK293 cells (which express endogenous P2Y1). The impaired signaling of the A87T mutant was dependent on co-expression with P2Y1, establishing that the A87T pathogenic effect operates through the P2Y1-P2Y11 hetero-oligomeric interaction.","method":"Site-directed mutagenesis; stable and transient expression in HEK293 and 1321N1 cells; Ca2+ assay; cAMP assay; receptor internalization assay","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct mutagenesis with multiple functional readouts, cell-context dependency systematically tested, mechanistic link to P2Y1 interaction established","pmids":["24524250"],"is_preprint":false},{"year":2014,"finding":"P2Y11 receptor activation by LXA4-stimulated apical ATP release (via Pannexin-1 channels) increased intracellular cAMP and Ca2+, restoring airway surface liquid height and promoting epithelial repair in cystic fibrosis airway cells. P2RY11 knockdown abolished the LXA4-induced increase in ASL height and epithelial wound repair.","method":"P2Y11 siRNA knockdown; pharmacological inhibitors of Pannexin-1 and P2Y11; cAMP/Ca2+ measurements; ASL height measurement; proliferation/migration/wound repair assays","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with functional readouts, single lab, multiple endpoints","pmids":["24588705"],"is_preprint":false},{"year":2016,"finding":"P2Y11R and P2X7R cooperatively inhibit migration of tumor-derived endothelial cells (BTECs) via calcium-dependent adenylyl cyclase 10 (AC10), cAMP release, and EPAC-1 activation. BzATP (P2X7 agonist/P2Y11 internalizer) mimicked the anti-migratory effect; pharmacological or molecular silencing of P2X7R and P2Y11R prevented it. P2Y11R stimulation also enhanced TEC-mediated pericyte attraction and reduced endothelial permeability.","method":"Pharmacological silencing and siRNA knockdown of P2X7R and P2Y11R; migration assays; cAMP measurement; AC10 identification; EPAC-1 activation","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA plus pharmacological, multiple functional readouts, single lab","pmids":["27586846"],"is_preprint":false},{"year":2019,"finding":"LPS stimulation of monocytes induces accumulation of extracellular ATP that suppresses T cell mitochondrial function, migration, IL-2 production, and proliferation via P2Y11 receptor activation on T cells. Enzymatic removal of extracellular ATP or P2Y11 antagonism partially restored T cell functions. This identifies P2Y11 as the receptor mediating LPS/monocyte-induced T cell immunosuppression.","method":"Pharmacological P2Y11 blockade; apyrase treatment; IL-2 ELISA; T cell proliferation assay; mitochondrial function assessment; extracellular ATP measurement","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological tools plus ATP removal, multiple functional readouts in primary human cells, single lab","pmids":["30787105"],"is_preprint":false},{"year":2019,"finding":"P2Y11 receptor stimulation at reoxygenation protected human AC16 cardiomyocytes against hypoxia/reoxygenation injury by reducing mitochondria-derived ROS and activating PKCε signaling pathway. The protection was abolished by P2Y11R antagonism.","method":"NF546 (agonist) and NF340 (antagonist) treatment; LDH assay; MTT assay; intracellular ATP measurement; mitochondrial ROS measurement; PKCε signaling pathway analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological agonist/antagonist with mechanistic pathway identification (PKCε), multiple cell viability readouts, single lab","pmids":["31406184"],"is_preprint":false},{"year":2020,"finding":"Autocrine P2Y11 receptor stimulation regulates polarization and migration of human CD4 T cells. P2Y11 redistributes from the front to the back of polarized T cells, where it triggers cAMP/PKA signaling that attenuates mitochondrial metabolism at the rear. The absence of P2Y11 at the front creates hotspots of mitochondrial activity and ATP production that stimulate P2X4 receptors and Ca2+ influx, driving pseudopod protrusion. Excessive global extracellular ATP (inflammation) disrupts this spatial autocrine loop and impairs T cell migration.","method":"Live-cell imaging of P2Y11 redistribution; pharmacological inhibition of P2Y11 and P2X4; cAMP/PKA signaling assays; mitochondrial metabolism imaging; migration assays","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Strong — live-cell imaging establishing subcellular redistribution with functional consequence, multiple orthogonal methods, clear mechanistic model validated by perturbation experiments","pmids":["32994212"],"is_preprint":false},{"year":2020,"finding":"P2Y11 receptors are essential for T cell activation at the immune synapse (IS): P2Y11 receptors retract to the back of cells where cAMP/PKA signaling redirects mitochondrial trafficking to the IS. This promotes aggregation of mitochondria with pannexin-1 ATP release channels and P2X4 receptors at the IS, sustaining local ATP production and Ca2+ influx needed for T cell activation.","method":"Live-cell imaging; pharmacological inhibition; mitochondria tracking; pannexin-1/P2X4 co-localization studies; Ca2+ measurements","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization tied to function, multiple pathway components examined, consistent with companion Science Signaling paper","pmids":["32531829"],"is_preprint":false},{"year":2022,"finding":"P2Y11 receptor activation in human M2 macrophages triggers canonical and IL-1 receptor signaling, upregulating IL-1R and its downstream targets (VEGF, CCL20, SOCS3) while downregulating CD39, P2X7, TLRs, and inflammasome components. cAMP elevation (via PDE4 inhibition) enhanced P2Y11-driven sTNFR2 shedding via TACE/ADAM17, with Epac1 differentially regulating downstream targets. Ca2+ and PKC also participated in P2Y11 signaling.","method":"Transcriptome/secretome profiling; NF340 antagonism; P2Y11 knockout cells; PDE4 inhibition; Epac1 inhibition; cytokine ELISAs; TACE/ADAM17 identification","journal":"Cellular and molecular life sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout cells, pharmacological controls, transcriptome + secretome dual profiling, multiple pathway components validated","pmids":["36107259"],"is_preprint":false},{"year":2024,"finding":"P2Y11 is the receptor on human colonic epithelial cells mediating HD5 (enteric α-defensin 5)-induced filopodial extensions via cAMP-PKA signaling. Multi-omics screening identified P2Y11 as the HD5 receptor; P2Y11 is distributed apically on colonic epithelium. Inhibitor screening confirmed cAMP-PKA as the main pathway for cytoskeleton-regulating activity of HD5, and P2Y11-mediated filopodia promote Shigella invasion.","method":"Multi-omics screening; in vitro cell assays; organoid model; gut-on-chip model; in vivo infection model; cAMP-PKA inhibitor pharmacology; immunolocalization","journal":"Nature microbiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-omics receptor identification validated in organoid, gut-on-chip, and in vivo models with pharmacological mechanism confirmation","pmids":["39901059"],"is_preprint":false},{"year":2024,"finding":"CXCR7 is an integral component of the P2Y11/IL-1R signaling cascade in human macrophages: P2Y11 activation upregulates CXCR7 and CXCR4, and CXCR7 agonism selectively enhanced P2Y11/IL-1R-mediated CCL20 secretion. CXCR4-associated PDE4 acts as a regulatory checkpoint for cAMP levels downstream of P2Y11; CXCR4 inactivation (which reduces PDE4 activity) removes cAMP degradation and amplifies P2Y11 signaling.","method":"Gene expression analysis; RNA interference (CXCR7 siRNA); pharmacological agonists/antagonists for P2Y11, CXCR4, CXCR7; PDE4 inhibition; CCL20 secretome analysis; astrocytoma cell line (natural CXCR7 expression, no CXCR4)","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown plus pharmacological tools, validated in multiple cell contexts, single lab","pmids":["38472446"],"is_preprint":false},{"year":2025,"finding":"P2Y11 receptor activates a P2Y11-FAK signaling axis in intestinal epithelial cells (in addition to the previously known PKA pathway). HD5 via P2Y11 induces phosphorylation of FAK and paxillin, promoting focal adhesion formation, with Rac1 acting downstream to support epithelial adhesion and barrier integrity. Cell-state-dependent bifurcation was shown: in well-adhered cells, HD5-P2Y11 engages PKA and induces protrusions; in suspended/injured cells, HD5-P2Y11 preferentially engages FAK for adhesion and barrier restoration.","method":"Primary human colonic epithelial cells; colonic organoids; gut-on-chip; FAK/paxillin phosphorylation assays; PKA inhibitor pharmacology; Rac1 pathway analysis; barrier integrity assays","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — multiple human-relevant models (primary cells, organoids, gut-on-chip) with biochemical signaling validation, single lab, novel pathway","pmids":["42144107"],"is_preprint":false},{"year":2000,"finding":"PKC differentially regulates P2Y11-mediated signaling in HL-60 cells: PMA-induced PKC activation inhibited PLC/Ca2+ responses but potentiated cAMP accumulation. PLC and adenylyl cyclase activation by P2Y11 were shown to operate through independent pathways (U-73122 blocked IP3/Ca2+ but not cAMP; SQ22536 blocked AC but not PLC).","method":"PKC activation/inhibition with PMA; PLC inhibitor U-73122; AC inhibitor SQ22536; IP3/Ca2+ and cAMP measurements in HL-60 cells","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — selective pathway inhibitors demonstrating independence of the two signaling arms, single lab","pmids":["11015299"],"is_preprint":false},{"year":2000,"finding":"P2Y11 receptor stimulation activates a cAMP signaling pathway that phosphorylates CREB and ATF-1 and drives renin promoter activity via the cAMP response element (CRE) at -222 in the REN promoter. Mutation of the CRE abolished the ATP/P2Y11 effect on renin reporter activity.","method":"Stable P2Y11 overexpression in Calu-6 cells; renin promoter-luciferase reporter assay; CRE mutagenesis; CREB/ATF-1 phosphorylation immunoblot; renin mRNA/protein measurement","journal":"Hypertension","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — promoter mutagenesis plus signaling pathway analysis, single lab, overexpression system","pmids":["11116131"],"is_preprint":false},{"year":2024,"finding":"P2RY11 deficiency in zebrafish (CRISPR/Cas9 knockout) reduced HCRT (hypocretin/orexin) expression and caused narcolepsy-like features. P2RY11 mutants also showed impaired neutrophil and macrophage recruitment to wound sites, altered cytokine balance (increased il6, tnfa, il1b; decreased il4, il10, tgfb), and reduced anti-inflammatory cytokines after tissue damage.","method":"CRISPR/Cas9 knockout; sleep behavior analysis; HCRT immunostaining/expression; neutrophil/macrophage migration assay at wound sites; cytokine expression analysis","journal":"Cell biology and toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with multiple functional readouts in an ortholog model, single lab","pmids":["38771396"],"is_preprint":false},{"year":2025,"finding":"P2Y11 receptor activation in human dendritic cells drives indoleamine-2,3-dioxygenase 1 (IDO1) upregulation through the noncanonical NF-κB signaling pathway. P2Y11R-mediated IDO1 upregulation was also associated with CD73 upregulation and adenosine production, leading to induction of PD-1-expressing suppressive T regulatory cells via A2AR. P2X7R inflammasome involvement in IDO1 upregulation was not confirmed.","method":"Pharmacological inhibition of P2Y11R; P2Y11R activation assays; IDO1/NF-κB pathway inhibitor studies; T regulatory cell induction assays; CD39/CD73/A2AR pharmacology","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway-specific inhibitors with multiple downstream functional readouts in primary DCs, single lab","pmids":["39899472"],"is_preprint":false}],"current_model":"P2Y11 is a Gq/Gs-coupled GPCR that uniquely couples to both phospholipase C (IP3/Ca2+) and adenylyl cyclase (cAMP/PKA) upon activation by extracellular ATP, NAD+, and NAADP+; it forms functional hetero-oligomers with P2Y1 that enable agonist-induced internalization and alter ligand selectivity; it redistributes subcellularly in polarized immune cells to spatially organize cAMP/PKA signaling and mitochondrial trafficking at the immune synapse; its ligand-binding pocket involves key residues Arg106, Glu186, Arg268, Arg307, and Tyr261; and it plays established roles in immune cell survival, DC maturation and tolerogenicity, neutrophil apoptosis delay, T cell migration and activation, macrophage polarization, and cardioprotection against ischemia/reperfusion injury through PKCε and EPAC1/cAMP-dependent mechanisms."},"narrative":{"mechanistic_narrative":"P2RY11 encodes P2Y11, a nucleotide-activated G protein-coupled receptor that uniquely couples to both phospholipase C (IP3/Ca2+) and adenylyl cyclase (cAMP/PKA), with the cAMP arm being weaker and the two pathways operating through independent effectors that can cross-talk via PKC and Ca2+ [PMID:10578132, PMID:11156592, PMID:11015299]. The receptor is activated by extracellular ATP and, beyond classical nucleotides, by the pyridine dinucleotides β-NAD+ and NAADP+, producing biphasic Ca2+ signals through combined IP3 and cAMP/cADPR mobilization [PMID:16926152, PMID:17707504]. Ligand recognition occurs through a defined binding pocket in which Arg106, Glu186, Arg268, and Arg307 engage the ATP phosphates while Tyr261 acts as an activation switch, and Arg268 specifically dictates stereospecific and triphosphate selectivity [PMID:17338680, PMID:18820714, PMID:11723245]. P2Y11 forms hetero-oligomers with P2Y1 that confer the agonist-induced internalization the receptor cannot otherwise undergo and alter its ligand selectivity; this interaction underlies the signaling deficit of the A87T variant [PMID:17824841, PMID:24524250]. Functionally, P2Y11 operates predominantly in immune and epithelial contexts through autocrine nucleotide loops: it drives dendritic cell maturation, tolerogenicity (IDO1/CD73-dependent Treg induction), and IL-8 release [PMID:11390464, PMID:19815812, PMID:39899472], delays neutrophil apoptosis [PMID:18056402], directs macrophage M1/M2 polarization and IL-1R/CXCR7 signaling [PMID:23577075, PMID:36107259, PMID:38472446], and spatially organizes cAMP/PKA signaling and mitochondrial trafficking in polarized T cells at the immune synapse to control migration and activation [PMID:32994212, PMID:32531829]. In epithelia it transduces α-defensin HD5 signals through bifurcating PKA-protrusion and FAK-adhesion pathways [PMID:39901059, PMID:42144107], and it confers cardioprotection against hypoxia/reoxygenation injury via PKCε [PMID:31406184]. A common P2RY11 SNP reducing receptor expression in CD8+ T and NK cells links the gene to narcolepsy, and zebrafish knockout reproduces narcolepsy-like reduction of hypocretin alongside impaired immune-cell recruitment [PMID:21170044, PMID:38771396].","teleology":[{"year":1999,"claim":"Established the foundational signaling identity of P2Y11 as a dually-coupled nucleotide receptor, answering what second-messenger pathways it engages and its agonist rank order.","evidence":"Recombinant expression in 1321N1 and CHO-K1 cells with IP3/cAMP pharmacological profiling","pmids":["10578132"],"confidence":"High","gaps":["Endogenous physiological agonist and tissue context not addressed","Relative coupling strength of the two arms not quantified"]},{"year":2001,"claim":"Defined the relationship between the two signaling arms, showing the cAMP arm is weaker than PLC coupling and that PKC/Ca2+ cross-talk potentiates cAMP, while also mapping a Gs-coupling and a key triphosphate-selectivity determinant.","evidence":"IP/cAMP/Ca2+ assays with PKC downregulation and BAPTA chelation; adenylyl cyclase assays in MDCK membranes; Arg265 mutagenesis comparing human and canine receptors","pmids":["11156592","11788591","11723245","11408597"],"confidence":"High","gaps":["Structural basis of dual G protein coupling not resolved","Whether cross-talk occurs in native immune cells not tested"]},{"year":2001,"claim":"Linked P2Y11 signaling to a concrete immune output by showing ATP drives dendritic cell maturation through P2Y11/cAMP/PKA, and revealed an unusual intergenic splicing event producing a functional P2Y11-SSF1 fusion.","evidence":"P2Y11 agonist profiling and H89 PKA inhibition in primary human DCs; cDNA cloning and functional expression of the fusion transcript","pmids":["11390464","11278528"],"confidence":"Medium","gaps":["No knockout confirmation in primary DCs","Physiological role of the SSF1 fusion protein unknown"]},{"year":2003,"claim":"Demonstrated agonist-biased signaling and a tissue-context restriction, showing UTP triggers a mechanistically distinct PTX-sensitive Ca2+ response and that DC maturation downregulates functional P2Y11.","evidence":"Ca2+ measurements with PTX and 2-APB in 1321N1 cells; migration assays and receptor expression analysis in DC subsets","pmids":["12761346","12649135"],"confidence":"Medium","gaps":["G protein identity underlying biased UTP response not isolated","Post-transcriptional regulation mechanism in blood DCs not defined"]},{"year":2007,"claim":"Broadened the agonist repertoire beyond nucleotides to the pyridine dinucleotides NAD+ and NAADP+, establishing P2Y11 as a multi-ligand sensor coupling to IP3, cAMP and cADPR in both recombinant and primary cells.","evidence":"Reconstitution in transfected vs wild-type 1321N1 cells with second-messenger measurements; siRNA and NF157 in primary granulocytes","pmids":["16926152","17707504"],"confidence":"High","gaps":["Whether dinucleotides bind the same pocket as ATP not directly resolved","Source/regulation of extracellular dinucleotides in vivo not defined"]},{"year":2007,"claim":"Mapped the ligand-binding pocket and identified Tyr261 as an activation switch, providing the structure-function basis for nucleotide recognition and dual coupling.","evidence":"Homology modeling with rhodopsin/P2Y1 templates and systematic mutagenesis with Ca2+/cAMP readouts; neutrophil apoptosis assays with NF157 and PKA inhibitors","pmids":["17338680","18056402"],"confidence":"High","gaps":["No experimental structure of the receptor","Why Gs coupling is more mutation-sensitive than Gq not explained"]},{"year":2008,"claim":"Resolved why P2Y11 lacks intrinsic endocytosis by demonstrating obligate hetero-oligomerization with P2Y1 that confers internalization and alters ligand selectivity, and pinpointed Arg268 as the stereospecificity determinant.","evidence":"Co-IP, pulldown and FRET with P2Y1 siRNA and internalization assays; mutagenesis with purified ATP-α-S diastereomers","pmids":["17824841","18820714"],"confidence":"High","gaps":["Stoichiometry and structural interface of the P2Y11-P2Y1 oligomer unknown","Whether oligomerization occurs in native immune cells not shown"]},{"year":2010,"claim":"Connected P2Y11 to human disease and tissue physiology, linking a expression-lowering SNP to immune-cell survival and identifying autocrine NAD+/ATP loops in stem cells and NK cells.","evidence":"GWAS with eQTL and cell-death assays in CD8+ T and NK cells; Cx43/P2Y11 siRNA in MSCs; pharmacological P2Y11 blockade in NK cytotoxicity assays","pmids":["21170044","20964598","20668227"],"confidence":"Medium","gaps":["SNP effect is on expression level rather than direct receptor function","Causal disease mechanism not established biochemically"]},{"year":2014,"claim":"Established that disease-associated receptor variants act through the P2Y1 hetero-oligomeric interface, showing the A87T polymorphism impairs signaling and abolishes internalization only when P2Y1 is co-expressed.","evidence":"Site-directed mutagenesis with Ca2+/cAMP/internalization assays in HEK293 (P2Y1+) vs 1321N1 cells; pharmacological P2Y11 work in CF airway epithelia","pmids":["24524250","24588705"],"confidence":"High","gaps":["Whether A87T contributes to specific clinical phenotypes not demonstrated","Generalizability of P2Y1-dependence to other variants untested"]},{"year":2019,"claim":"Defined autocrine ATP-release-coupled P2Y11 circuits as drivers of inflammatory output, controlling macrophage M1 polarization, keratinocyte IL-6, T-cell immunosuppression, and cardioprotective PKCε signaling.","evidence":"VNUT/SLC17A9 and P2Y11 siRNA with in vivo LPS model; P2Y11 knockdown and pharmacology in keratinocytes and T cells; NF546/NF340 in AC16 cardiomyocytes","pmids":["23577075","23461851","30787105","31406184"],"confidence":"High","gaps":["Source of physiological ATP varies by cell type and is incompletely mapped","Branch-point determining pro- vs anti-inflammatory outcome unclear"]},{"year":2020,"claim":"Revealed a spatial signaling mechanism in which P2Y11 redistributes within polarized T cells to compartmentalize cAMP/PKA and mitochondrial activity, coordinating migration and immune-synapse activation with P2X4 and pannexin-1.","evidence":"Live-cell imaging of receptor redistribution, mitochondrial metabolism imaging, and P2X4/P2Y11 pharmacology in human CD4 T cells","pmids":["32994212","32531829"],"confidence":"High","gaps":["Molecular machinery driving receptor redistribution unknown","How global ATP elevation overrides the spatial loop not mechanistically detailed"]},{"year":2022,"claim":"Expanded P2Y11 signaling networks in macrophages, linking it to IL-1R/CXCR7 cross-regulation, Epac1-differential targets, and a CXCR4-PDE4 cAMP checkpoint.","evidence":"Transcriptome/secretome profiling with P2Y11 knockout cells, PDE4/Epac1 inhibition, CXCR7 siRNA, and chemokine-receptor pharmacology","pmids":["36107259","38472446"],"confidence":"High","gaps":["Direct physical interaction between P2Y11 and IL-1R/CXCR7 not shown","Generalizability beyond M2 macrophages untested"]},{"year":2024,"claim":"Identified P2Y11 as a defensin receptor and established its in vivo role in epithelial cytoskeletal remodeling and host-pathogen interaction, while a zebrafish knockout connected the gene to hypocretin and immune-cell recruitment.","evidence":"Multi-omics receptor identification with organoid, gut-on-chip and in vivo Shigella models; CRISPR/Cas9 zebrafish knockout with sleep, HCRT and wound-recruitment phenotypes","pmids":["39901059","38771396"],"confidence":"Medium","gaps":["Direct HD5-P2Y11 binding affinity not quantified","Mechanistic basis of the hypocretin link not established"]},{"year":2025,"claim":"Showed cell-state-dependent pathway bifurcation downstream of P2Y11, with PKA driving protrusion in adhered cells and a FAK/paxillin/Rac1 axis driving adhesion and barrier repair in injured cells, and a tolerogenic NF-κB/IDO1 arm in dendritic cells.","evidence":"Primary colonic epithelial cells, organoids and gut-on-chip with FAK/paxillin phosphorylation and PKA/Rac1 analysis; pathway-inhibitor studies and Treg induction assays in DCs","pmids":["42144107","39899472"],"confidence":"Medium","gaps":["Switch mechanism selecting PKA vs FAK output not molecularly defined","Single-lab findings for the FAK axis"]},{"year":null,"claim":"How a single receptor integrates multiple ligand classes and selects among cAMP/PKA, FAK, PKCε, and oligomerization-dependent outputs in a cell-state- and context-specific manner remains the central open mechanistic question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimental receptor structure or active-state model","Determinants of pathway and partner selection across cell types undefined","In vivo physiological agonist for each context not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,9,11,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,26,29]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,32]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,19,26,28]}],"complexes":["P2Y11-P2Y1 hetero-oligomer"],"partners":["P2RY1","P2RX4","P2RX7","ACKR3","CXCR4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96G91","full_name":"P2Y purinoceptor 11","aliases":[],"length_aa":374,"mass_kda":40.3,"function":"Receptor for ATP and ADP coupled to G-proteins that activate both phosphatidylinositol-calcium and adenylyl cyclase second messenger systems. Not activated by UTP or UDP","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q96G91/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/P2RY11","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/P2RY11","total_profiled":1310},"omim":[{"mim_id":"614223","title":"NARCOLEPSY 6, SUSCEPTIBILITY TO; NRCLP6","url":"https://www.omim.org/entry/614223"},{"mim_id":"607793","title":"PETER PAN, DROSOPHILA, HOMOLOG OF; PPAN","url":"https://www.omim.org/entry/607793"},{"mim_id":"602697","title":"PURINERGIC RECEPTOR P2Y, G PROTEIN-COUPLED, 11; P2RY11","url":"https://www.omim.org/entry/602697"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/P2RY11"},"hgnc":{"alias_symbol":["P2Y11"],"prev_symbol":[]},"alphafold":{"accession":"Q96G91","domains":[{"cath_id":"1.20.1070.10","chopping":"26-325","consensus_level":"high","plddt":90.3646,"start":26,"end":325}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96G91","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96G91-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96G91-F1-predicted_aligned_error_v6.png","plddt_mean":80.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=P2RY11","jax_strain_url":"https://www.jax.org/strain/search?query=P2RY11"},"sequence":{"accession":"Q96G91","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96G91.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96G91/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96G91"}},"corpus_meta":[{"pmid":"10578132","id":"PMC_10578132","title":"Pharmacological characterization of the human P2Y11 receptor.","date":"1999","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10578132","citation_count":209,"is_preprint":false},{"pmid":"21170044","id":"PMC_21170044","title":"Common variants in P2RY11 are associated with narcolepsy.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21170044","citation_count":175,"is_preprint":false},{"pmid":"11390464","id":"PMC_11390464","title":"The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11390464","citation_count":150,"is_preprint":false},{"pmid":"16926152","id":"PMC_16926152","title":"Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16926152","citation_count":113,"is_preprint":false},{"pmid":"23577075","id":"PMC_23577075","title":"Autocrine regulation of macrophage activation via exocytosis of ATP and activation of P2Y11 receptor.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23577075","citation_count":110,"is_preprint":false},{"pmid":"18056402","id":"PMC_18056402","title":"Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18056402","citation_count":100,"is_preprint":false},{"pmid":"12649135","id":"PMC_12649135","title":"ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12649135","citation_count":95,"is_preprint":false},{"pmid":"19815812","id":"PMC_19815812","title":"NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.","date":"2009","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19815812","citation_count":88,"is_preprint":false},{"pmid":"17824841","id":"PMC_17824841","title":"Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor.","date":"2008","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17824841","citation_count":81,"is_preprint":false},{"pmid":"16250663","id":"PMC_16250663","title":"Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16250663","citation_count":80,"is_preprint":false},{"pmid":"11754592","id":"PMC_11754592","title":"Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.","date":"2002","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11754592","citation_count":76,"is_preprint":false},{"pmid":"12761346","id":"PMC_12761346","title":"Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12761346","citation_count":74,"is_preprint":false},{"pmid":"27246167","id":"PMC_27246167","title":"A critical look at the function of the P2Y11 receptor.","date":"2016","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27246167","citation_count":65,"is_preprint":false},{"pmid":"27586846","id":"PMC_27586846","title":"Activation of P2X7 and P2Y11 purinergic receptors inhibits migration and normalizes tumor-derived endothelial cells via cAMP signaling.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27586846","citation_count":62,"is_preprint":false},{"pmid":"24886406","id":"PMC_24886406","title":"Role of spinal P2Y6 and P2Y11 receptors in neuropathic pain in rats: possible involvement of glial cells.","date":"2014","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/24886406","citation_count":61,"is_preprint":false},{"pmid":"11278528","id":"PMC_11278528","title":"Cotranscription and intergenic splicing of human P2Y11 and SSF1 genes.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278528","citation_count":57,"is_preprint":false},{"pmid":"15893764","id":"PMC_15893764","title":"Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors.","date":"2005","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15893764","citation_count":56,"is_preprint":false},{"pmid":"11156592","id":"PMC_11156592","title":"Differential coupling of the human P2Y(11) receptor to phospholipase C and adenylyl cyclase.","date":"2001","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11156592","citation_count":54,"is_preprint":false},{"pmid":"17135283","id":"PMC_17135283","title":"Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-87 variant of the ATP receptor P2Y11.","date":"2006","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/17135283","citation_count":50,"is_preprint":false},{"pmid":"20964598","id":"PMC_20964598","title":"Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling.","date":"2010","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/20964598","citation_count":50,"is_preprint":false},{"pmid":"20668227","id":"PMC_20668227","title":"ATP secreted by endothelial cells blocks CX₃CL 1-elicited natural killer cell chemotaxis and cytotoxicity via P2Y₁₁ receptor activation.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20668227","citation_count":49,"is_preprint":false},{"pmid":"11292586","id":"PMC_11292586","title":"P2Y(11), a purinergic receptor acting via cAMP, mediates secretion by pancreatic duct epithelial cells.","date":"2001","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11292586","citation_count":46,"is_preprint":false},{"pmid":"11788591","id":"PMC_11788591","title":"P2Y11 receptors activate adenylyl cyclase and contribute to nucleotide-promoted cAMP formation in MDCK-D(1) cells. A mechanism for nucleotide-mediated autocrine-paracrine regulation.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11788591","citation_count":44,"is_preprint":false},{"pmid":"32994212","id":"PMC_32994212","title":"The purinergic receptor P2Y11 choreographs the polarization, mitochondrial metabolism, and migration of T lymphocytes.","date":"2020","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32994212","citation_count":43,"is_preprint":false},{"pmid":"29134605","id":"PMC_29134605","title":"P2Y11 Receptors: Properties, Distribution and Functions.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/29134605","citation_count":42,"is_preprint":false},{"pmid":"11129961","id":"PMC_11129961","title":"Pharmacological characterisation of the P2Y11 receptor in stably transfected haematological cell lines.","date":"2000","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11129961","citation_count":42,"is_preprint":false},{"pmid":"25449358","id":"PMC_25449358","title":"Participation of peripheral P2Y1, P2Y6 and P2Y11 receptors in formalin-induced inflammatory pain in rats.","date":"2014","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/25449358","citation_count":41,"is_preprint":false},{"pmid":"18048695","id":"PMC_18048695","title":"Involvement of P2Y1 and P2Y11 purinoceptors in parasympathetic inhibition of colonic smooth muscle.","date":"2007","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18048695","citation_count":41,"is_preprint":false},{"pmid":"17338680","id":"PMC_17338680","title":"Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis.","date":"2007","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/17338680","citation_count":40,"is_preprint":false},{"pmid":"17707504","id":"PMC_17707504","title":"NAADP+ is an agonist of the human P2Y11 purinergic receptor.","date":"2007","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/17707504","citation_count":40,"is_preprint":false},{"pmid":"11723245","id":"PMC_11723245","title":"An arginine/glutamine difference at the juxtaposition of transmembrane domain 6 and the third extracellular loop contributes to the markedly different nucleotide selectivities of human and canine P2Y11 receptors.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11723245","citation_count":39,"is_preprint":false},{"pmid":"24588705","id":"PMC_24588705","title":"Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis.","date":"2014","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24588705","citation_count":38,"is_preprint":false},{"pmid":"11408597","id":"PMC_11408597","title":"Cloning, expression, signaling mechanisms, and membrane targeting of P2Y(11) receptors in Madin Darby canine kidney cells.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11408597","citation_count":37,"is_preprint":false},{"pmid":"19748117","id":"PMC_19748117","title":"Extracellular NAD(+) induces a rise in [Ca(2+)](i) in activated human monocytes via engagement of P2Y(1) and P2Y(11) receptors.","date":"2009","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/19748117","citation_count":36,"is_preprint":false},{"pmid":"28418839","id":"PMC_28418839","title":"Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28418839","citation_count":35,"is_preprint":false},{"pmid":"26078273","id":"PMC_26078273","title":"Hypoxia/Reoxygenation Inhibits P2Y11 Receptor Expression and Its Immunosuppressive Activity in Human Dendritic Cells.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26078273","citation_count":31,"is_preprint":false},{"pmid":"23182888","id":"PMC_23182888","title":"P2Y11 purinoceptor mediates the ATP-enhanced chemotactic response of rat neutrophils.","date":"2012","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23182888","citation_count":30,"is_preprint":false},{"pmid":"10947861","id":"PMC_10947861","title":"Signal transduction and white cell maturation via extracellular ATP and the P2Y11 receptor.","date":"2000","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10947861","citation_count":29,"is_preprint":false},{"pmid":"30787105","id":"PMC_30787105","title":"Lipopolysaccharide suppresses T cells by generating extracellular ATP that impairs their mitochondrial function via P2Y11 receptors.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30787105","citation_count":29,"is_preprint":false},{"pmid":"26324417","id":"PMC_26324417","title":"Calcium signaling and the novel anti-proliferative effect of the UTP-sensitive P2Y11 receptor in rat cardiac myofibroblasts.","date":"2015","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/26324417","citation_count":27,"is_preprint":false},{"pmid":"16953187","id":"PMC_16953187","title":"Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5'-O-(alpha-boranotriphosphate) analogues.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16953187","citation_count":27,"is_preprint":false},{"pmid":"11527539","id":"PMC_11527539","title":"P2Y(11) receptor expression by human lymphocytes: evidence for two cAMP-linked purinoceptors.","date":"2001","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11527539","citation_count":27,"is_preprint":false},{"pmid":"23583195","id":"PMC_23583195","title":"Extracellular NAADP affords cardioprotection against ischemia and reperfusion injury and involves the P2Y11-like receptor.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23583195","citation_count":24,"is_preprint":false},{"pmid":"23461851","id":"PMC_23461851","title":"Involvement of P2Y₁₁ receptor in IFN-γ-induced IL-6 production in human keratinocytes.","date":"2013","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23461851","citation_count":23,"is_preprint":false},{"pmid":"17941622","id":"PMC_17941622","title":"New iantherans from the marine sponge Ianthella quadrangulata: novel agonists of the P2Y(11) receptor.","date":"2007","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17941622","citation_count":21,"is_preprint":false},{"pmid":"31406184","id":"PMC_31406184","title":"Stimulation of P2Y11 receptor protects human cardiomyocytes against Hypoxia/Reoxygenation injury and involves PKCε signaling pathway.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31406184","citation_count":20,"is_preprint":false},{"pmid":"32531829","id":"PMC_32531829","title":"Frontline Science: P2Y11 receptors support T cell activation by directing mitochondrial trafficking to the immune synapse.","date":"2020","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/32531829","citation_count":19,"is_preprint":false},{"pmid":"31447857","id":"PMC_31447857","title":"The Human G Protein-Coupled ATP Receptor P2Y11 Is Associated With IL-10 Driven Macrophage Differentiation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31447857","citation_count":19,"is_preprint":false},{"pmid":"31618941","id":"PMC_31618941","title":"ATP-Evoked Intracellular Ca2+ Responses in M-CSF Differentiated Human Monocyte-Derived Macrophage are Mediated by P2X4 and P2Y11 Receptor Activation.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31618941","citation_count":19,"is_preprint":false},{"pmid":"11116131","id":"PMC_11116131","title":"Capacity for purinergic control of renin promoter via P2Y(11) receptor and cAMP pathways.","date":"2000","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/11116131","citation_count":19,"is_preprint":false},{"pmid":"34503103","id":"PMC_34503103","title":"ATP Inhibits Breast Cancer Migration and Bone Metastasis through Down-Regulation of CXCR4 and Purinergic Receptor P2Y11.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34503103","citation_count":18,"is_preprint":false},{"pmid":"36107259","id":"PMC_36107259","title":"The P2Y11 receptor of human M2 macrophages activates canonical and IL-1 receptor signaling to translate the extracellular danger signal ATP into anti-inflammatory and pro-angiogenic responses.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/36107259","citation_count":18,"is_preprint":false},{"pmid":"28213772","id":"PMC_28213772","title":"The effect of purinergic signaling via the P2Y11 receptor on vascular function in a rat model of acute inflammation.","date":"2017","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28213772","citation_count":18,"is_preprint":false},{"pmid":"24524250","id":"PMC_24524250","title":"Alanine-(87)-threonine polymorphism impairs signaling and internalization of the human P2Y11 receptor, when co-expressed with the P2Y1 receptor.","date":"2014","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24524250","citation_count":17,"is_preprint":false},{"pmid":"23726915","id":"PMC_23726915","title":"Intracellular NAADP increase induced by extracellular NAADP via the P2Y11-like receptor.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23726915","citation_count":17,"is_preprint":false},{"pmid":"21503959","id":"PMC_21503959","title":"P2Y11 impairs cell proliferation by induction of cell cycle arrest and sensitizes endothelial cells to cisplatin-induced cell death.","date":"2011","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21503959","citation_count":17,"is_preprint":false},{"pmid":"30031814","id":"PMC_30031814","title":"Stimulation of P2Y11 receptor modulates cardiac fibroblasts secretome toward immunomodulatory and protective roles after Hypoxia/Reoxygenation injury.","date":"2018","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30031814","citation_count":16,"is_preprint":false},{"pmid":"33463722","id":"PMC_33463722","title":"The human G protein-coupled ATP receptor P2Y11 is a target for anti-inflammatory strategies.","date":"2021","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33463722","citation_count":16,"is_preprint":false},{"pmid":"18820714","id":"PMC_18820714","title":"Diastereoselectivity of the P2Y11 nucleotide receptor: mutational analysis.","date":"2008","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18820714","citation_count":15,"is_preprint":false},{"pmid":"25015314","id":"PMC_25015314","title":"UTP is not a biased agonist at human P2Y(11) receptors.","date":"2014","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25015314","citation_count":15,"is_preprint":false},{"pmid":"24793913","id":"PMC_24793913","title":"Involvement of P2Y11 receptor in silica nanoparticles 30-induced IL-6 production by human keratinocytes.","date":"2014","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/24793913","citation_count":14,"is_preprint":false},{"pmid":"32142768","id":"PMC_32142768","title":"Modulation of P2Y11-related purinergic signaling in inflammation and cardio-metabolic diseases.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32142768","citation_count":11,"is_preprint":false},{"pmid":"11015299","id":"PMC_11015299","title":"Differential regulation of P2Y(11) receptor-mediated signalling to phospholipase C and adenylyl cyclase by protein kinase C in HL-60 promyelocytes.","date":"2000","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11015299","citation_count":11,"is_preprint":false},{"pmid":"31066305","id":"PMC_31066305","title":"The antagonist of P2Y11 receptor NF157 ameliorates oxidized LDL-induced vascular endothelial inflammation.","date":"2019","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31066305","citation_count":10,"is_preprint":false},{"pmid":"23810430","id":"PMC_23810430","title":"Sp-2-propylthio-ATP-α-B and Sp-2-propylthio-ATP-α-B,β-γ-dichloromethylene are novel potent and specific agonists of the human P2Y₁₁ receptor.","date":"2013","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23810430","citation_count":9,"is_preprint":false},{"pmid":"30711276","id":"PMC_30711276","title":"Stimulation of murine P2Y11-like purinoreceptor protects against hypoxia/reoxygenation injury and decreases heart graft rejection lesions.","date":"2018","source":"The Journal of thoracic and cardiovascular surgery","url":"https://pubmed.ncbi.nlm.nih.gov/30711276","citation_count":9,"is_preprint":false},{"pmid":"33467058","id":"PMC_33467058","title":"P2Y11 Agonism Prevents Hypoxia/Reoxygenation- and Angiotensin II-Induced Vascular Dysfunction and Intimal Hyperplasia Development.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33467058","citation_count":8,"is_preprint":false},{"pmid":"31301116","id":"PMC_31301116","title":"P2Y11 receptor antagonist NF340 ameliorates inflammation in human fibroblast-like synoviocytes: An implication in rheumatoid arthritis.","date":"2019","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/31301116","citation_count":8,"is_preprint":false},{"pmid":"29553088","id":"PMC_29553088","title":"A Novel Mechanism of γ-Irradiation-Induced IL-6 Production Mediated by P2Y11 Receptor in Epidermal Keratinocytes.","date":"2018","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/29553088","citation_count":8,"is_preprint":false},{"pmid":"33710305","id":"PMC_33710305","title":"High nocturnal sleep fragmentation is associated with low T lymphocyte P2Y11 protein levels in narcolepsy type 1.","date":"2021","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/33710305","citation_count":7,"is_preprint":false},{"pmid":"33232731","id":"PMC_33232731","title":"P2Y4, P2Y6 and P2Y11 receptors: From the early days of cloning to their function.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33232731","citation_count":7,"is_preprint":false},{"pmid":"27515691","id":"PMC_27515691","title":"Validation of antibodies for neuroanatomical localization of the P2Y11 receptor in macaque brain.","date":"2016","source":"Journal of chemical neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/27515691","citation_count":7,"is_preprint":false},{"pmid":"30076967","id":"PMC_30076967","title":"Inhibition of cytokine-mediated JNK signalling by purinergic P2Y11 receptors, a novel protective mechanism in endothelial cells.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30076967","citation_count":7,"is_preprint":false},{"pmid":"39901059","id":"PMC_39901059","title":"Shigella infection is facilitated by interaction of human enteric α-defensin 5 with colonic epithelial receptor P2Y11.","date":"2025","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/39901059","citation_count":6,"is_preprint":false},{"pmid":"31497195","id":"PMC_31497195","title":"Antagonism of P2Y11 receptor (P2Y11R) protects epidermal stem cells against UV-B irradiation.","date":"2019","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/31497195","citation_count":6,"is_preprint":false},{"pmid":"37881155","id":"PMC_37881155","title":"Systematic P2Y receptor survey identifies P2Y11 as modulator of immune responses and virus replication in macrophages.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/37881155","citation_count":5,"is_preprint":false},{"pmid":"30144157","id":"PMC_30144157","title":"Adenosine diphosphate-sensitive P2Y11 receptor inhibits endothelial cell proliferation by induction of cell cycle arrest in the S phase and induces the expression of inflammatory mediators.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30144157","citation_count":4,"is_preprint":false},{"pmid":"38771396","id":"PMC_38771396","title":"Deficiency of P2RY11 causes narcolepsy and attenuates the recruitment of neutrophils and macrophages in the inflammatory response in zebrafish.","date":"2024","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/38771396","citation_count":3,"is_preprint":false},{"pmid":"31450027","id":"PMC_31450027","title":"Altered surface expression of P2Y11 receptor with narcolepsy-associated mutations.","date":"2019","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/31450027","citation_count":2,"is_preprint":false},{"pmid":"38472446","id":"PMC_38472446","title":"Crosstalk between purinergic receptor P2Y11 and chemokine receptor CXCR7 is regulated by CXCR4 in human macrophages.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38472446","citation_count":2,"is_preprint":false},{"pmid":"39899472","id":"PMC_39899472","title":"Noncanonical NF-κB signaling in dendritic cells is required for ATP-driven indoleamine 2,3-dioxygenase 1 induction through P2Y11 receptor.","date":"2025","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/39899472","citation_count":2,"is_preprint":false},{"pmid":"42144107","id":"PMC_42144107","title":"Human enteric defensin 5 protects intestinal barrier integrity via cell state-dependent P2Y11-FAK-Rac1 signaling.","date":"2026","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/42144107","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.09.30.615810","title":"Ectonucleotidases and Purinergic Receptors in Mouse Prostate Gland","date":"2024-10-01","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.30.615810","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48335,"output_tokens":9926,"usd":0.146948,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20394,"output_tokens":5085,"usd":0.114547,"stage2_stop_reason":"end_turn"},"total_usd":0.261495,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"P2Y11 receptor is dually coupled to both phosphoinositide (PLC) and adenylyl cyclase (cAMP) pathways upon activation by ATP. The rank order of agonist potency was: ATPγS ≈ BzATP > dATP > ATP > ADPβS > 2MeSATP. Suramin acted as a competitive antagonist (Ki ~0.82 µM). AR-C67085 was identified as the most potent agonist.\",\n      \"method\": \"Stable recombinant expression in 1321N1 astrocytoma cells (IP3 assay) and CHO-K1 cells (cAMP assay); pharmacological characterization with agonists and antagonists\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro pharmacological reconstitution in two independent cell lines, replicated across multiple nucleotides and pathways\",\n      \"pmids\": [\"10578132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"P2Y11 receptor mediates ATP-induced maturation of human monocyte-derived dendritic cells through the P2Y11/cAMP/protein kinase A signaling pathway. The rank order of potency of ATP analogs matched the P2Y11 receptor profile, and the PKA inhibitor H89 blocked nucleotide-induced DC maturation (CD83 upregulation and IL-12 secretion).\",\n      \"method\": \"Pharmacological profiling with P2Y11-selective agonists/antagonists; PKA inhibitor (H89) functional assay; cAMP measurement in DCs\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological approaches in primary human cells, single lab, no siRNA/knockout confirmation\",\n      \"pmids\": [\"11390464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The P2Y11 gene and the adjacent SSF1 gene are co-transcribed and undergo intergenic splicing, producing a chimeric P2Y11-SSF1 fusion transcript that is ubiquitously expressed in human tissues. The fusion protein retains P2Y11 receptor function (cAMP response to ATP) when stably expressed in CHO-K1 cells.\",\n      \"method\": \"cDNA library screening; RT-PCR; stable expression in CHO-K1 cells; cAMP assay; Western blotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct molecular cloning with functional validation, single lab\",\n      \"pmids\": [\"11278528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Coupling of the human P2Y11 receptor to adenylyl cyclase is significantly weaker than coupling to phospholipase C (ATP is ~15-fold less potent for cAMP vs. IP accumulation). PKC activation and intracellular Ca2+ mobilization (downstream of PLC) potentiate P2Y11-mediated cAMP accumulation, indicating cross-talk between the two signaling arms.\",\n      \"method\": \"Stable expression in 1321N1 and CHO cells; IP/cAMP assays; PKC downregulation with phorbol ester; intracellular Ca2+ chelation with BAPTA\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal biochemical approaches in two independent cell lines, rigorous controls\",\n      \"pmids\": [\"11156592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The canine P2Y11 receptor shows preferential activation by ADP nucleotides (opposite to the human P2Y11 which prefers ATP nucleotides). Mutational analysis revealed that Arg-265 at the juxtaposition of TM6 and the third extracellular loop in hP2Y11 is a key determinant of triphosphate selectivity; substituting it with glutamine (as found in cP2Y11) shifts selectivity toward diphosphates.\",\n      \"method\": \"Stable expression of human and canine P2Y11 in CHO-K1 and 1321N1 cells; IP/cAMP assays; Ca2+ mobilization; site-directed mutagenesis of Arg265\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — site-directed mutagenesis with functional readout in multiple cell lines, orthogonal assays\",\n      \"pmids\": [\"11723245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"P2Y11 receptor couples to Gs to directly activate adenylyl cyclase in canine MDCK-D1 cells, stimulating PI hydrolysis, Ca2+ mobilization, and cAMP accumulation. Microscopy and short-circuit current measurements demonstrated primarily basolateral targeting of P2Y11 receptors in polarized MDCK-D1 cell monolayers.\",\n      \"method\": \"Cloning and stable expression of cP2Y11-GFP; fluorescence microscopy; Ussing chamber electrophysiology; PKC inhibition; eicosanoid inhibition controls\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with functional consequence (basolateral Isc response), single lab\",\n      \"pmids\": [\"11408597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"P2Y11 receptors in MDCK-D1 cells activate adenylyl cyclase via Gs, producing indo-resistant cAMP. ADP analogs (ADPβS, MT-ADP) activated adenylyl cyclase in MDCK membranes directly, and the response was synergistic with forskolin, confirming Gs-coupling. Overexpressed GFP-tagged P2Y11 receptors confirmed this pharmacological profile.\",\n      \"method\": \"Stable expression of GFP-tagged P2Y11 in MDCK-D1 cells; cAMP assays; adenylyl cyclase activity assay in membranes; antagonist pharmacology; indomethacin treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct adenylyl cyclase assay in membranes plus cell-based cAMP, single lab\",\n      \"pmids\": [\"11788591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"UTP activates a Ca2+ mobilizing response at P2Y11 receptors that is mechanistically distinct from the ATP-mediated response: UTP-induced Ca2+ is less dependent on extracellular Ca2+, is sensitive to pertussis toxin (unlike ATP), and is more easily desensitized. No P2Y2 or P2Y4 mRNA was detected in the expressing cells, confirming the response is P2Y11-mediated. This represents agonist-specific (biased) signaling at a single receptor.\",\n      \"method\": \"Stable expression in 1321N1 cells; intracellular Ca2+ measurements; RT-PCR for P2Y2/P2Y4; pertussis toxin pretreatment; 2-APB treatment; desensitization experiments\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal pharmacological/molecular methods, single lab\",\n      \"pmids\": [\"12761346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"P2Y11 receptor activation inhibits migration of monocyte-derived DCs (MoDCs) and CD1a+ dermal DCs in a dose-dependent manner. On maturation, MoDCs downregulated P2Y11 receptor expression and became less sensitive to ATP-mediated migration inhibition. Blood DC subtypes did not respond to P2Y11R agonists despite mRNA expression, indicating post-transcriptional regulation of functional receptor expression.\",\n      \"method\": \"P2Y receptor agonist/antagonist pharmacology; Ca2+ flux studies; migration assays; flow cytometry; RT-PCR\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple DC populations, pharmacological and receptor expression approaches, functional migration assay, single lab\",\n      \"pmids\": [\"12649135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Extracellular β-NAD+ is an agonist of the P2Y11 receptor. In hP2Y11-transfected 1321N1 astrocytoma cells, but not untransfected cells, NAD+ promoted IP3, cAMP, and cADPR production and biphasic Ca2+ elevation. In human granulocytes, selective P2Y11 inhibition (NF157) and P2Y11 siRNA knockdown prevented NAD+-induced Ca2+ increase and chemotaxis.\",\n      \"method\": \"Stable transfection in 1321N1 cells; IP3/cAMP/cADPR measurements; Ca2+ imaging; siRNA knockdown; pharmacological inhibition with NF157 in primary granulocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in transfected cells plus siRNA in primary cells, multiple second messengers measured, replicated across cell types\",\n      \"pmids\": [\"16926152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"P2Y11 receptor mediates ATP-induced inhibition of neutrophil apoptosis via downstream activation of type I cAMP-dependent protein kinases (PKA). Brief (10 min) ATP exposure caused long-lasting apoptosis delay. The P2Y11 antagonist NF157 abrogated the anti-apoptotic effect; the mechanism was not mediated by adenosine (ATP breakdown product).\",\n      \"method\": \"Morphology, annexin V/To-Pro3 staining, mitochondrial membrane permeabilization assay; NF157 antagonism; PKA inhibition; receptor expression studies; cAMP measurements\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple apoptosis readouts and signaling inhibitors, single lab\",\n      \"pmids\": [\"18056402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NAADP+ is an agonist of the human P2Y11 receptor. In hP2Y11-transfected 1321N1 cells (but not wild-type), extracellular NAADP+ triggered concentration-dependent biphasic Ca2+ elevation via IP3 (rapid phase) and cAMP/cADPR (sustained phase). In human granulocytes, NF157 confirmed endogenous P2Y11 mediated NAADP+-induced cell activation.\",\n      \"method\": \"Stable transfection in 1321N1 cells; IP3/cAMP/cADPR measurements; Ca2+ imaging; NF157 pharmacological inhibition in primary granulocytes\",\n      \"journal\": \"Cell calcium\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in transfected vs. wild-type cells, multiple second messengers, confirmed in primary cells\",\n      \"pmids\": [\"17707504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Computational homology modeling combined with mutagenesis identified the ligand-binding site residues of P2Y11: Arg106, Glu186, Arg268, and Arg307 interact ionically with ATP phosphate moieties; Tyr261 acts as a molecular switch (Y261A mutant is inactive); Phe109 provides minor π-stacking with adenine; Ser206 H-bonds to γ-phosphate; Ala313 contributes to a hydrophobic pocket near C-2 of ATP. Gs coupling efficacy was more variable across mutants than Gq coupling.\",\n      \"method\": \"Homology modeling with bovine rhodopsin and hP2Y1-ATP templates; site-directed mutagenesis of Arg106, Glu186, Arg268, Arg307, Phe109, Tyr261, Ser206, Ala313, Met310; Ca2+ and cAMP functional assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple point mutations with functional readouts across two signaling pathways, rigorous structure-function analysis\",\n      \"pmids\": [\"17338680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"P2Y11 and P2Y1 receptors form hetero-oligomers when co-expressed. This association (detected by co-pulldown, immunoprecipitation, and FRET) promotes agonist-induced internalization of P2Y11, which by itself cannot undergo endocytosis. P2Y11 co-internalized with P2Y1 upon ATP or P2Y1-selective agonist (2-MeS-ADP) stimulation, and siRNA knockdown of endogenous P2Y1 in HEK293 cells reduced GFP-P2Y11 endocytosis. The hetero-oligomerization also altered ligand selectivity of P2Y11.\",\n      \"method\": \"Co-pulldown; immunoprecipitation; FRET; siRNA knockdown of P2Y1; Ca2+ imaging; stable co-expression in HEK293 and 1321N1 cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — three orthogonal methods (co-IP, pulldown, FRET) for complex detection, functional internalization confirmed by siRNA, single lab but multiple approaches\",\n      \"pmids\": [\"17824841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Arg268 in TM6 is the principal determinant of P2Y11 receptor stereospecificity for Pα-substituted ATP derivatives. R268A and R268Q mutations abolished stereoselective recognition of ATP-α-S isomers. Glu186A mutation increased stereoselectivity. The double mutant R268Q/E186A showed additive decrease in potency but no additional stereoselectivity change.\",\n      \"method\": \"Site-directed mutagenesis; Ca2+ assay with purified diastereomers of ATP-α-S; molecular modeling\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous mutagenesis with purified stereoisomers, multiple mutants with systematic structure-activity analysis\",\n      \"pmids\": [\"18820714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NF546 is the first selective non-nucleotide P2Y11 agonist, acting at the same binding site as ATPγS (as shown by competitive Schild analysis with antagonist NF340, pA2 = 8.02–8.04). NF546 stimulated IL-8 release from monocyte-derived dendritic cells, a P2Y11-mediated effect blocked by NF340.\",\n      \"method\": \"Schild analysis; Ca2+ and cAMP assays in transfected 1321N1 cells; molecular modeling; IL-8 ELISA in primary DCs; NF340 antagonism\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — competitive pharmacology (Schild analysis) plus functional assays in both recombinant and primary cells, rigorous binding-site characterization\",\n      \"pmids\": [\"19815812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The disease-associated P2RY11 SNP (rs2305795) correlates with reduced P2Y11 expression in CD8+ T lymphocytes and NK cells, and reduced P2Y11-mediated resistance to ATP-induced cell death in these cells. This identifies P2Y11 as a regulator of immune-cell survival.\",\n      \"method\": \"Genome-wide association study with replication; eQTL analysis; flow cytometry for cell death in T and NK cells\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell death assay linked to expression levels, replicated across ethnic groups, but mechanism is expression-level rather than direct biochemical\",\n      \"pmids\": [\"21170044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"P2Y11 receptor activation by extracellular NAD+ (released via Connexin 43 hemichannels) mediates an autocrine cAMP/cADPR/Ca2+ signaling cascade in human mesenchymal stem cells, involving L-type Ca2+ channel opening. This signaling promoted MSC proliferation, migration, prostaglandin E2 release, cytokine release, and downregulation of T lymphocyte proliferation.\",\n      \"method\": \"Cx43 siRNA; NAD+ glycohydrolase treatment; P2Y11 siRNA; cAMP/cADPR/Ca2+ measurements; L-type channel pharmacology; functional assays (proliferation, migration)\",\n      \"journal\": \"Stem cells and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown of P2Y11 and Cx43 with multiple functional readouts, single lab\",\n      \"pmids\": [\"20964598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"P2Y11 receptor activation on NK cells mediates ATP-induced inhibition of CX3CL1-directed NK cell chemotaxis and cytotoxicity against endothelial cells. This inhibitory effect correlated with increased intracellular cAMP. Pharmacological inhibition of P2Y11R (or apyrase addition) removed the protective effect on endothelial cells from NK-mediated killing.\",\n      \"method\": \"Pharmacological inhibition of P2Y11R; cAMP measurement; chemotaxis assay; NK cell cytotoxicity assay against HUVECs and coronary artery ECs\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in primary cells with pharmacological tools, single lab\",\n      \"pmids\": [\"20668227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ATP release via vesicular exocytosis (VNUT/SLC17A9-dependent) followed by autocrine P2Y11 receptor activation is a major pathway for LPS-induced macrophage activation and cytokine release. Knockdown of SLC17A9, NF157 (P2Y11 antagonist), or P2Y11 siRNA knockdown suppressed M1 polarization and IL-6 production in THP-1 cells. In vivo, NF157 suppressed LPS-induced proinflammatory cytokines and macrophage M1 polarization.\",\n      \"method\": \"siRNA knockdown of SLC17A9 and P2Y11; ATP release measurement; pharmacological inhibition with NF157; in vivo LPS mouse model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA knockdown of both upstream transporter and receptor with multiple functional readouts, validated in vivo, multiple orthogonal approaches\",\n      \"pmids\": [\"23577075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"P2Y11 receptor mediates IFN-γ-induced IL-6 production in human keratinocytes (HaCaT cells) via an autocrine ATP loop. IFN-γ stimulated ATP release; NF157 (P2Y11 antagonist), apyrase, suramin, and P2Y11 knockdown all suppressed IL-6 production. A soluble adenylate cyclase inhibitor (KH7) also blocked the effect, implicating cAMP signaling.\",\n      \"method\": \"P2Y11 siRNA knockdown; pharmacological inhibitors (NF157, suramin, apyrase, KH7); IL-6 ELISA; ATP release measurement\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA plus multiple pharmacological approaches, single lab\",\n      \"pmids\": [\"23461851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The Ala-87-Thr (A87T) polymorphism of P2Y11 impairs signaling (reduced Ca2+ response to BzATP, reduced cAMP) and completely abolishes agonist-induced receptor internalization in HEK293 cells (which express endogenous P2Y1). The impaired signaling of the A87T mutant was dependent on co-expression with P2Y1, establishing that the A87T pathogenic effect operates through the P2Y1-P2Y11 hetero-oligomeric interaction.\",\n      \"method\": \"Site-directed mutagenesis; stable and transient expression in HEK293 and 1321N1 cells; Ca2+ assay; cAMP assay; receptor internalization assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct mutagenesis with multiple functional readouts, cell-context dependency systematically tested, mechanistic link to P2Y1 interaction established\",\n      \"pmids\": [\"24524250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"P2Y11 receptor activation by LXA4-stimulated apical ATP release (via Pannexin-1 channels) increased intracellular cAMP and Ca2+, restoring airway surface liquid height and promoting epithelial repair in cystic fibrosis airway cells. P2RY11 knockdown abolished the LXA4-induced increase in ASL height and epithelial wound repair.\",\n      \"method\": \"P2Y11 siRNA knockdown; pharmacological inhibitors of Pannexin-1 and P2Y11; cAMP/Ca2+ measurements; ASL height measurement; proliferation/migration/wound repair assays\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with functional readouts, single lab, multiple endpoints\",\n      \"pmids\": [\"24588705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"P2Y11R and P2X7R cooperatively inhibit migration of tumor-derived endothelial cells (BTECs) via calcium-dependent adenylyl cyclase 10 (AC10), cAMP release, and EPAC-1 activation. BzATP (P2X7 agonist/P2Y11 internalizer) mimicked the anti-migratory effect; pharmacological or molecular silencing of P2X7R and P2Y11R prevented it. P2Y11R stimulation also enhanced TEC-mediated pericyte attraction and reduced endothelial permeability.\",\n      \"method\": \"Pharmacological silencing and siRNA knockdown of P2X7R and P2Y11R; migration assays; cAMP measurement; AC10 identification; EPAC-1 activation\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA plus pharmacological, multiple functional readouts, single lab\",\n      \"pmids\": [\"27586846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LPS stimulation of monocytes induces accumulation of extracellular ATP that suppresses T cell mitochondrial function, migration, IL-2 production, and proliferation via P2Y11 receptor activation on T cells. Enzymatic removal of extracellular ATP or P2Y11 antagonism partially restored T cell functions. This identifies P2Y11 as the receptor mediating LPS/monocyte-induced T cell immunosuppression.\",\n      \"method\": \"Pharmacological P2Y11 blockade; apyrase treatment; IL-2 ELISA; T cell proliferation assay; mitochondrial function assessment; extracellular ATP measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological tools plus ATP removal, multiple functional readouts in primary human cells, single lab\",\n      \"pmids\": [\"30787105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"P2Y11 receptor stimulation at reoxygenation protected human AC16 cardiomyocytes against hypoxia/reoxygenation injury by reducing mitochondria-derived ROS and activating PKCε signaling pathway. The protection was abolished by P2Y11R antagonism.\",\n      \"method\": \"NF546 (agonist) and NF340 (antagonist) treatment; LDH assay; MTT assay; intracellular ATP measurement; mitochondrial ROS measurement; PKCε signaling pathway analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological agonist/antagonist with mechanistic pathway identification (PKCε), multiple cell viability readouts, single lab\",\n      \"pmids\": [\"31406184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Autocrine P2Y11 receptor stimulation regulates polarization and migration of human CD4 T cells. P2Y11 redistributes from the front to the back of polarized T cells, where it triggers cAMP/PKA signaling that attenuates mitochondrial metabolism at the rear. The absence of P2Y11 at the front creates hotspots of mitochondrial activity and ATP production that stimulate P2X4 receptors and Ca2+ influx, driving pseudopod protrusion. Excessive global extracellular ATP (inflammation) disrupts this spatial autocrine loop and impairs T cell migration.\",\n      \"method\": \"Live-cell imaging of P2Y11 redistribution; pharmacological inhibition of P2Y11 and P2X4; cAMP/PKA signaling assays; mitochondrial metabolism imaging; migration assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live-cell imaging establishing subcellular redistribution with functional consequence, multiple orthogonal methods, clear mechanistic model validated by perturbation experiments\",\n      \"pmids\": [\"32994212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"P2Y11 receptors are essential for T cell activation at the immune synapse (IS): P2Y11 receptors retract to the back of cells where cAMP/PKA signaling redirects mitochondrial trafficking to the IS. This promotes aggregation of mitochondria with pannexin-1 ATP release channels and P2X4 receptors at the IS, sustaining local ATP production and Ca2+ influx needed for T cell activation.\",\n      \"method\": \"Live-cell imaging; pharmacological inhibition; mitochondria tracking; pannexin-1/P2X4 co-localization studies; Ca2+ measurements\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization tied to function, multiple pathway components examined, consistent with companion Science Signaling paper\",\n      \"pmids\": [\"32531829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"P2Y11 receptor activation in human M2 macrophages triggers canonical and IL-1 receptor signaling, upregulating IL-1R and its downstream targets (VEGF, CCL20, SOCS3) while downregulating CD39, P2X7, TLRs, and inflammasome components. cAMP elevation (via PDE4 inhibition) enhanced P2Y11-driven sTNFR2 shedding via TACE/ADAM17, with Epac1 differentially regulating downstream targets. Ca2+ and PKC also participated in P2Y11 signaling.\",\n      \"method\": \"Transcriptome/secretome profiling; NF340 antagonism; P2Y11 knockout cells; PDE4 inhibition; Epac1 inhibition; cytokine ELISAs; TACE/ADAM17 identification\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout cells, pharmacological controls, transcriptome + secretome dual profiling, multiple pathway components validated\",\n      \"pmids\": [\"36107259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"P2Y11 is the receptor on human colonic epithelial cells mediating HD5 (enteric α-defensin 5)-induced filopodial extensions via cAMP-PKA signaling. Multi-omics screening identified P2Y11 as the HD5 receptor; P2Y11 is distributed apically on colonic epithelium. Inhibitor screening confirmed cAMP-PKA as the main pathway for cytoskeleton-regulating activity of HD5, and P2Y11-mediated filopodia promote Shigella invasion.\",\n      \"method\": \"Multi-omics screening; in vitro cell assays; organoid model; gut-on-chip model; in vivo infection model; cAMP-PKA inhibitor pharmacology; immunolocalization\",\n      \"journal\": \"Nature microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-omics receptor identification validated in organoid, gut-on-chip, and in vivo models with pharmacological mechanism confirmation\",\n      \"pmids\": [\"39901059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CXCR7 is an integral component of the P2Y11/IL-1R signaling cascade in human macrophages: P2Y11 activation upregulates CXCR7 and CXCR4, and CXCR7 agonism selectively enhanced P2Y11/IL-1R-mediated CCL20 secretion. CXCR4-associated PDE4 acts as a regulatory checkpoint for cAMP levels downstream of P2Y11; CXCR4 inactivation (which reduces PDE4 activity) removes cAMP degradation and amplifies P2Y11 signaling.\",\n      \"method\": \"Gene expression analysis; RNA interference (CXCR7 siRNA); pharmacological agonists/antagonists for P2Y11, CXCR4, CXCR7; PDE4 inhibition; CCL20 secretome analysis; astrocytoma cell line (natural CXCR7 expression, no CXCR4)\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown plus pharmacological tools, validated in multiple cell contexts, single lab\",\n      \"pmids\": [\"38472446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"P2Y11 receptor activates a P2Y11-FAK signaling axis in intestinal epithelial cells (in addition to the previously known PKA pathway). HD5 via P2Y11 induces phosphorylation of FAK and paxillin, promoting focal adhesion formation, with Rac1 acting downstream to support epithelial adhesion and barrier integrity. Cell-state-dependent bifurcation was shown: in well-adhered cells, HD5-P2Y11 engages PKA and induces protrusions; in suspended/injured cells, HD5-P2Y11 preferentially engages FAK for adhesion and barrier restoration.\",\n      \"method\": \"Primary human colonic epithelial cells; colonic organoids; gut-on-chip; FAK/paxillin phosphorylation assays; PKA inhibitor pharmacology; Rac1 pathway analysis; barrier integrity assays\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple human-relevant models (primary cells, organoids, gut-on-chip) with biochemical signaling validation, single lab, novel pathway\",\n      \"pmids\": [\"42144107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PKC differentially regulates P2Y11-mediated signaling in HL-60 cells: PMA-induced PKC activation inhibited PLC/Ca2+ responses but potentiated cAMP accumulation. PLC and adenylyl cyclase activation by P2Y11 were shown to operate through independent pathways (U-73122 blocked IP3/Ca2+ but not cAMP; SQ22536 blocked AC but not PLC).\",\n      \"method\": \"PKC activation/inhibition with PMA; PLC inhibitor U-73122; AC inhibitor SQ22536; IP3/Ca2+ and cAMP measurements in HL-60 cells\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — selective pathway inhibitors demonstrating independence of the two signaling arms, single lab\",\n      \"pmids\": [\"11015299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"P2Y11 receptor stimulation activates a cAMP signaling pathway that phosphorylates CREB and ATF-1 and drives renin promoter activity via the cAMP response element (CRE) at -222 in the REN promoter. Mutation of the CRE abolished the ATP/P2Y11 effect on renin reporter activity.\",\n      \"method\": \"Stable P2Y11 overexpression in Calu-6 cells; renin promoter-luciferase reporter assay; CRE mutagenesis; CREB/ATF-1 phosphorylation immunoblot; renin mRNA/protein measurement\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter mutagenesis plus signaling pathway analysis, single lab, overexpression system\",\n      \"pmids\": [\"11116131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"P2RY11 deficiency in zebrafish (CRISPR/Cas9 knockout) reduced HCRT (hypocretin/orexin) expression and caused narcolepsy-like features. P2RY11 mutants also showed impaired neutrophil and macrophage recruitment to wound sites, altered cytokine balance (increased il6, tnfa, il1b; decreased il4, il10, tgfb), and reduced anti-inflammatory cytokines after tissue damage.\",\n      \"method\": \"CRISPR/Cas9 knockout; sleep behavior analysis; HCRT immunostaining/expression; neutrophil/macrophage migration assay at wound sites; cytokine expression analysis\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with multiple functional readouts in an ortholog model, single lab\",\n      \"pmids\": [\"38771396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"P2Y11 receptor activation in human dendritic cells drives indoleamine-2,3-dioxygenase 1 (IDO1) upregulation through the noncanonical NF-κB signaling pathway. P2Y11R-mediated IDO1 upregulation was also associated with CD73 upregulation and adenosine production, leading to induction of PD-1-expressing suppressive T regulatory cells via A2AR. P2X7R inflammasome involvement in IDO1 upregulation was not confirmed.\",\n      \"method\": \"Pharmacological inhibition of P2Y11R; P2Y11R activation assays; IDO1/NF-κB pathway inhibitor studies; T regulatory cell induction assays; CD39/CD73/A2AR pharmacology\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway-specific inhibitors with multiple downstream functional readouts in primary DCs, single lab\",\n      \"pmids\": [\"39899472\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"P2Y11 is a Gq/Gs-coupled GPCR that uniquely couples to both phospholipase C (IP3/Ca2+) and adenylyl cyclase (cAMP/PKA) upon activation by extracellular ATP, NAD+, and NAADP+; it forms functional hetero-oligomers with P2Y1 that enable agonist-induced internalization and alter ligand selectivity; it redistributes subcellularly in polarized immune cells to spatially organize cAMP/PKA signaling and mitochondrial trafficking at the immune synapse; its ligand-binding pocket involves key residues Arg106, Glu186, Arg268, Arg307, and Tyr261; and it plays established roles in immune cell survival, DC maturation and tolerogenicity, neutrophil apoptosis delay, T cell migration and activation, macrophage polarization, and cardioprotection against ischemia/reperfusion injury through PKCε and EPAC1/cAMP-dependent mechanisms.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"P2RY11 encodes P2Y11, a nucleotide-activated G protein-coupled receptor that uniquely couples to both phospholipase C (IP3/Ca2+) and adenylyl cyclase (cAMP/PKA), with the cAMP arm being weaker and the two pathways operating through independent effectors that can cross-talk via PKC and Ca2+ [#0, #3, #32]. The receptor is activated by extracellular ATP and, beyond classical nucleotides, by the pyridine dinucleotides β-NAD+ and NAADP+, producing biphasic Ca2+ signals through combined IP3 and cAMP/cADPR mobilization [#9, #11]. Ligand recognition occurs through a defined binding pocket in which Arg106, Glu186, Arg268, and Arg307 engage the ATP phosphates while Tyr261 acts as an activation switch, and Arg268 specifically dictates stereospecific and triphosphate selectivity [#12, #14, #4]. P2Y11 forms hetero-oligomers with P2Y1 that confer the agonist-induced internalization the receptor cannot otherwise undergo and alter its ligand selectivity; this interaction underlies the signaling deficit of the A87T variant [#13, #21]. Functionally, P2Y11 operates predominantly in immune and epithelial contexts through autocrine nucleotide loops: it drives dendritic cell maturation, tolerogenicity (IDO1/CD73-dependent Treg induction), and IL-8 release [#1, #15, #35], delays neutrophil apoptosis [#10], directs macrophage M1/M2 polarization and IL-1R/CXCR7 signaling [#19, #28, #30], and spatially organizes cAMP/PKA signaling and mitochondrial trafficking in polarized T cells at the immune synapse to control migration and activation [#26, #27]. In epithelia it transduces α-defensin HD5 signals through bifurcating PKA-protrusion and FAK-adhesion pathways [#29, #31], and it confers cardioprotection against hypoxia/reoxygenation injury via PKCε [#25]. A common P2RY11 SNP reducing receptor expression in CD8+ T and NK cells links the gene to narcolepsy, and zebrafish knockout reproduces narcolepsy-like reduction of hypocretin alongside impaired immune-cell recruitment [#16, #34].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established the foundational signaling identity of P2Y11 as a dually-coupled nucleotide receptor, answering what second-messenger pathways it engages and its agonist rank order.\",\n      \"evidence\": \"Recombinant expression in 1321N1 and CHO-K1 cells with IP3/cAMP pharmacological profiling\",\n      \"pmids\": [\"10578132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological agonist and tissue context not addressed\", \"Relative coupling strength of the two arms not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined the relationship between the two signaling arms, showing the cAMP arm is weaker than PLC coupling and that PKC/Ca2+ cross-talk potentiates cAMP, while also mapping a Gs-coupling and a key triphosphate-selectivity determinant.\",\n      \"evidence\": \"IP/cAMP/Ca2+ assays with PKC downregulation and BAPTA chelation; adenylyl cyclase assays in MDCK membranes; Arg265 mutagenesis comparing human and canine receptors\",\n      \"pmids\": [\"11156592\", \"11788591\", \"11723245\", \"11408597\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of dual G protein coupling not resolved\", \"Whether cross-talk occurs in native immune cells not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Linked P2Y11 signaling to a concrete immune output by showing ATP drives dendritic cell maturation through P2Y11/cAMP/PKA, and revealed an unusual intergenic splicing event producing a functional P2Y11-SSF1 fusion.\",\n      \"evidence\": \"P2Y11 agonist profiling and H89 PKA inhibition in primary human DCs; cDNA cloning and functional expression of the fusion transcript\",\n      \"pmids\": [\"11390464\", \"11278528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No knockout confirmation in primary DCs\", \"Physiological role of the SSF1 fusion protein unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated agonist-biased signaling and a tissue-context restriction, showing UTP triggers a mechanistically distinct PTX-sensitive Ca2+ response and that DC maturation downregulates functional P2Y11.\",\n      \"evidence\": \"Ca2+ measurements with PTX and 2-APB in 1321N1 cells; migration assays and receptor expression analysis in DC subsets\",\n      \"pmids\": [\"12761346\", \"12649135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"G protein identity underlying biased UTP response not isolated\", \"Post-transcriptional regulation mechanism in blood DCs not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Broadened the agonist repertoire beyond nucleotides to the pyridine dinucleotides NAD+ and NAADP+, establishing P2Y11 as a multi-ligand sensor coupling to IP3, cAMP and cADPR in both recombinant and primary cells.\",\n      \"evidence\": \"Reconstitution in transfected vs wild-type 1321N1 cells with second-messenger measurements; siRNA and NF157 in primary granulocytes\",\n      \"pmids\": [\"16926152\", \"17707504\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether dinucleotides bind the same pocket as ATP not directly resolved\", \"Source/regulation of extracellular dinucleotides in vivo not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapped the ligand-binding pocket and identified Tyr261 as an activation switch, providing the structure-function basis for nucleotide recognition and dual coupling.\",\n      \"evidence\": \"Homology modeling with rhodopsin/P2Y1 templates and systematic mutagenesis with Ca2+/cAMP readouts; neutrophil apoptosis assays with NF157 and PKA inhibitors\",\n      \"pmids\": [\"17338680\", \"18056402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental structure of the receptor\", \"Why Gs coupling is more mutation-sensitive than Gq not explained\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved why P2Y11 lacks intrinsic endocytosis by demonstrating obligate hetero-oligomerization with P2Y1 that confers internalization and alters ligand selectivity, and pinpointed Arg268 as the stereospecificity determinant.\",\n      \"evidence\": \"Co-IP, pulldown and FRET with P2Y1 siRNA and internalization assays; mutagenesis with purified ATP-α-S diastereomers\",\n      \"pmids\": [\"17824841\", \"18820714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural interface of the P2Y11-P2Y1 oligomer unknown\", \"Whether oligomerization occurs in native immune cells not shown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected P2Y11 to human disease and tissue physiology, linking a expression-lowering SNP to immune-cell survival and identifying autocrine NAD+/ATP loops in stem cells and NK cells.\",\n      \"evidence\": \"GWAS with eQTL and cell-death assays in CD8+ T and NK cells; Cx43/P2Y11 siRNA in MSCs; pharmacological P2Y11 blockade in NK cytotoxicity assays\",\n      \"pmids\": [\"21170044\", \"20964598\", \"20668227\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SNP effect is on expression level rather than direct receptor function\", \"Causal disease mechanism not established biochemically\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that disease-associated receptor variants act through the P2Y1 hetero-oligomeric interface, showing the A87T polymorphism impairs signaling and abolishes internalization only when P2Y1 is co-expressed.\",\n      \"evidence\": \"Site-directed mutagenesis with Ca2+/cAMP/internalization assays in HEK293 (P2Y1+) vs 1321N1 cells; pharmacological P2Y11 work in CF airway epithelia\",\n      \"pmids\": [\"24524250\", \"24588705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether A87T contributes to specific clinical phenotypes not demonstrated\", \"Generalizability of P2Y1-dependence to other variants untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined autocrine ATP-release-coupled P2Y11 circuits as drivers of inflammatory output, controlling macrophage M1 polarization, keratinocyte IL-6, T-cell immunosuppression, and cardioprotective PKCε signaling.\",\n      \"evidence\": \"VNUT/SLC17A9 and P2Y11 siRNA with in vivo LPS model; P2Y11 knockdown and pharmacology in keratinocytes and T cells; NF546/NF340 in AC16 cardiomyocytes\",\n      \"pmids\": [\"23577075\", \"23461851\", \"30787105\", \"31406184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of physiological ATP varies by cell type and is incompletely mapped\", \"Branch-point determining pro- vs anti-inflammatory outcome unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a spatial signaling mechanism in which P2Y11 redistributes within polarized T cells to compartmentalize cAMP/PKA and mitochondrial activity, coordinating migration and immune-synapse activation with P2X4 and pannexin-1.\",\n      \"evidence\": \"Live-cell imaging of receptor redistribution, mitochondrial metabolism imaging, and P2X4/P2Y11 pharmacology in human CD4 T cells\",\n      \"pmids\": [\"32994212\", \"32531829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery driving receptor redistribution unknown\", \"How global ATP elevation overrides the spatial loop not mechanistically detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded P2Y11 signaling networks in macrophages, linking it to IL-1R/CXCR7 cross-regulation, Epac1-differential targets, and a CXCR4-PDE4 cAMP checkpoint.\",\n      \"evidence\": \"Transcriptome/secretome profiling with P2Y11 knockout cells, PDE4/Epac1 inhibition, CXCR7 siRNA, and chemokine-receptor pharmacology\",\n      \"pmids\": [\"36107259\", \"38472446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between P2Y11 and IL-1R/CXCR7 not shown\", \"Generalizability beyond M2 macrophages untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified P2Y11 as a defensin receptor and established its in vivo role in epithelial cytoskeletal remodeling and host-pathogen interaction, while a zebrafish knockout connected the gene to hypocretin and immune-cell recruitment.\",\n      \"evidence\": \"Multi-omics receptor identification with organoid, gut-on-chip and in vivo Shigella models; CRISPR/Cas9 zebrafish knockout with sleep, HCRT and wound-recruitment phenotypes\",\n      \"pmids\": [\"39901059\", \"38771396\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HD5-P2Y11 binding affinity not quantified\", \"Mechanistic basis of the hypocretin link not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed cell-state-dependent pathway bifurcation downstream of P2Y11, with PKA driving protrusion in adhered cells and a FAK/paxillin/Rac1 axis driving adhesion and barrier repair in injured cells, and a tolerogenic NF-κB/IDO1 arm in dendritic cells.\",\n      \"evidence\": \"Primary colonic epithelial cells, organoids and gut-on-chip with FAK/paxillin phosphorylation and PKA/Rac1 analysis; pathway-inhibitor studies and Treg induction assays in DCs\",\n      \"pmids\": [\"42144107\", \"39899472\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Switch mechanism selecting PKA vs FAK output not molecularly defined\", \"Single-lab findings for the FAK axis\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single receptor integrates multiple ligand classes and selects among cAMP/PKA, FAK, PKCε, and oligomerization-dependent outputs in a cell-state- and context-specific manner remains the central open mechanistic question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental receptor structure or active-state model\", \"Determinants of pathway and partner selection across cell types undefined\", \"In vivo physiological agonist for each context not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 9, 11, 12]},\n      {\"term_id\": \"GO:0004930\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 26, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 32]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 19, 26, 28]}\n    ],\n    \"complexes\": [\"P2Y11-P2Y1 hetero-oligomer\"],\n    \"partners\": [\"P2RY1\", \"P2RX4\", \"P2RX7\", \"ACKR3\", \"CXCR4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}